Histaminergic regulation of natural killer cell-mediated clearance of tumour cells in mice.
Treatment of Swiss albino mice with histamine enhanced the clearance of natural killer (NK)-cell sensitive YAC-1 lymphoma and B16/F10 melanoma cells from lung tissue in vivo, but did not affect the elimination of NK-cell-insensitive P815 mastocytoma cells. The effect of histamine was apparently mediated by H2-type histamine receptors (H2R) since it was blocked by ranitidine, and H2R antagonist. Histamine did not affect clearance of tumour cells in animals depleted of NK cells in vivo by treatment with antibodies to asialo-GM1 or NK1.1. The effect of histamine was time-dependent: pretreatment with histamine for 3 h significantly augmented the clearance of YAC-1 cells, whereas, pretreatment with histamine for 5 min was ineffective. Histamine potentiated the anti-tumour properties of NK-cell activators such as interleukin-2 (IL-2) or interferon-alpha (IFN-alpha) in vivo. None of these lymphokines significantly affected the clearance of YAC-1 cells unless animals were concomitantly treated with histamine. Treatment with ranitidine alone reduced the in vivo clearance of YAC-1 cells from lungs but did not affect the clearance of NK-cell-insensitive P815 cells. Effects of ranitidine on NK-cell function in vivo were not shared by a chemical control to ranitidine, AH20239AA, thus indicating that the inhibition of NK-cells results from H2R antagonism rather than non-specific toxicity. It is concluded that histaminergic mechanisms may be involved in the regulation of NK cell function in vivo.
Asea
A
A
Department of Clinical Virology, University of Göteborg, Gothenburg, Sweden.
Hermodsson
S
S
Hellstrand
K
K
D000818:Animals; D000906:Antibodies / Q000494:pharmacology; D003602:Cytotoxicity, Immunologic / Q000187:drug effects; D005260:Female; D005677:G(M1) Ganglioside / Q000276:immunology; D006632:Histamine / Q000494:pharmacology*; D006635:Histamine H2 Antagonists / Q000494:pharmacology; D007111:Immunity, Cellular; D016898:Interferon-alpha / Q000494:pharmacology; D007376:Interleukin-2 / Q000494:pharmacology; D007694:Killer Cells, Natural / Q000187:drug effects / Q000502:physiology*; D008175:Lung Neoplasms / Q000276:immunology / Q000503:physiopathology*; D008223:Lymphoma / Q000276:immunology / Q000503:physiopathology*; D008546:Melanoma, Experimental / Q000276:immunology / Q000503:physiopathology*; D051379:Mice; D011899:Ranitidine / Q000031:analogs & derivatives / Q000494:pharmacology; D011970:Receptors, Histamine H2 / Q000502:physiology
C097861:AH 20239AA; D000906:Antibodies; D006635:Histamine H2 Antagonists; D016898:Interferon-alpha; D007376:Interleukin-2; D011970:Receptors, Histamine H2; D005677:G(M1) Ganglioside; C018835:asialo GM1 ganglioside; D006632:Histamine; D011899:Ranitidine